{"id":19346,"date":"2023-04-25T17:13:08","date_gmt":"2023-04-25T17:13:08","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19346"},"modified":"2023-04-25T17:40:05","modified_gmt":"2023-04-25T17:40:05","slug":"sysmex-europe-se-has-signed-a-multi-market-emea-distribution-agreement-with-cerca-biotech-the-company-behind-the-innovative-breast-cancer-diagnostic-assay-mammatyper","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/sysmex-europe-se-has-signed-a-multi-market-emea-distribution-agreement-with-cerca-biotech-the-company-behind-the-innovative-breast-cancer-diagnostic-assay-mammatyper\/","title":{"rendered":"Sysmex Europe SE has signed a multi-market EMEA distribution agreement with Cerca Biotech, the company behind the innovative breast cancer diagnostic assay \u2013 MammaTyper\u00ae"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

Sysmex Europe SE has signed a multi-market EMEA distribution agreement with Cerca Biotech, the company behind the innovative breast cancer diagnostic assay \u2013 MammaTyper\u00ae<\/h1>\/ in E-News<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n
\"\"<\/div><\/div><\/div>
\n

As a result of the agreement,\u00a0MammaTyper\u00ae\u00a0<\/sup>will become part of the Sysmex Life Science portfolio in 13 territories across EMEA, including the UK, Ireland and the majority of mainland Europe.<\/h3>\n

<\/p>\n

MammaTyper\u00ae<\/sup> is the first real innovation in subtyping breast cancer in decades. Using RT-qPCR technology proven during the COVID-19 pandemic, the multigene test works through an easily replicated and quantitative measurement of marker gene expression, classifying each sample as a St. Gallen molecular subtype. MammaTyper\u00ae<\/sup> provides standardised, objective results and can also accurately assess HER2-low tumours and Ki-67 markers, offering a reliable basis for selecting the best treatment option for patients.<\/p>\n

By being robustly reproducible, it avoids many of the common pre-analytical errors in the pathology laboratory, especially for the proliferation marker Ki-67 \u2013 critical in luminal subtyping and prognosis. Using MammaTyper\u00ae\u00a0to subtype breast cancer tissue is a valuable resource for pathologists and can provide the reassurance with accurate subtyping for tailored treatment which are patient-specific.<\/p>\n

By sharing deep scientific knowledge and an understanding of clinical needs, Sysmex Life Science and Cerca Biotech will work closely together to enable individualised breast cancer diagnostics across many markets.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

Richard Hughes, Director at Cerca Biotech:\u00a0<\/strong><\/h4>\n

\u201cRepeatable, reproducible testing is the only way we can ensure that every person diagnosed with breast cancer can access the best treatment for their individual case.\u00a0Through this partnership with Sysmex\u00a0Europe,\u00a0MammaTyper\u00ae<\/sup> will be available as a valuable diagnostic tool to more pathologists in more markets across Europe. We are proud that MammaTyper\u00ae<\/sup>will be part of Sysmex\u2019s cutting-edge portfolio.\u201d<\/p>\n

Samantha Giangregorio, Head of Life Science, Vice President Sysmex Europe SE:\u00a0<\/strong><\/h4>\n

\u201cWe are excited to be collaborating with\u00a0Cerca\u00a0Biotech and\u00a0to extend\u00a0and strengthen\u00a0our\u00a0innovative\u00a0molecular portfolio,\u00a0building on the success of our\u00a0OSNA\u00ae<\/sup> solution in breast cancer. Considering the clinical need for accurate and individualised diagnostics, the MammaTyper\u00ae<\/sup> can play a key role in the breast cancer diagnostic pathway, providing guidance for the right treatment, thus improving the quality of life of patients.\u201d<\/p>\n

For more information, visit\u00a0www.sysmex-europe.com<\/a>.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

MammaTyper kits<\/em><\/p>\n<\/div><\/section>
\n